Solution How It Works Compliance Check ROI Calculator 14-Day Sprint Events Intelligence About Us
Contact
Login Contact Book Demo →
For Regulated Life Sciences Teams & Agencies

Improve Marketing Assets.Reduce Rework.Move Faster to Market.

OmniVynt helps life sciences marketing teams and agencies reduce rework, align claims and evidence, improve collaboration, and prepare cleaner assets for formal review.

Book Demo
See How It Works Model ROI Start 14-Day Proof Sprint
Advisory-only · Glass-box logic · Medical Legal Review retains full authority · PIPEDA compliant · Zero IT setup
53%
Faster content development
Pre-MLR drafting & internal review
44%
Fewer PAAB resubmissions
1.6 → ~0.9 cycles per asset
22.75 → 10.75
Internal hours per asset
Modeled workflow compression
Based on PAAB 2025 Tag Report, 2026 fee schedule, and modeled agency workflows. Advisory-only AI. Economic impact varies by asset complexity, team structure, and internal review process.

See What OmniVynt Catches

Upload a claim or asset and see risk, PM boundary, and evidence gaps flagged in real time.

  • Clause-level PAAB flags
  • PM boundary checks
  • Evidence-linkage gaps
  • Rewrite options per flag
  • Approval score
Scan Your File Free →
Pharma, Biotech, Medical Device, Medtech, Diagnostics, AI/Digital Health

3 Life Sciences Marketing Execution Gaps

Fragmented workflows, compliance friction, and weak claims create avoidable delay. OmniVynt helps fix that upstream.

1. Fragmented Data & Omnichannel Coordination +

The Problem: Claims, evidence, drafts, and comments split across systems create version chaos and weak handoffs.

OmniVynt Solution: One system for claims, evidence, collaboration, and compliance decisions keeps work aligned before review.

2. Regulatory & AI Compliance Complexity +

The Problem: Teams are expected to move faster while proving every claim, output, and decision.

OmniVynt Solution: Source-verified flags and rewrite guidance strengthen submissions while keeping reviewer authority intact.

3. Asset Quality & Message Credibility +

The Problem: Weak claims, uneven fair balance, and lower asset quality reduce trust with HCPs, stakeholders, and patients.

OmniVynt Solution: Earlier claim-evidence and fair-balance checks strengthen Claim Credibility & Fair Balance while helping teams produce stronger review-ready assets.

Model the Business Case → Book Demo →
Sources. 1 Omnichannel coordination challenge framed around fragmented claims, evidence, drafts, and review inputs in regulated marketing workflows. 2 Regulatory pressure reflects PAAB, FDA/OPDP, privacy, AI governance, and internal review standards already referenced across the site. 3 Credible content section reflects OmniVynt’s role in improving claims, statements, and fair balance earlier in development. 4 Metrics mirror existing site benchmarks based on PAAB 2025 Tag Report, 2026 fee schedule, and modeled agency workflows; actual results vary by asset complexity and team structure.
Why OmniVynt

From Brief to Submission-Ready in One Session

Watch how OmniVynt catches claim risk, strengthens evidence alignment, and generates audit-ready outputs before a single asset reaches formal review, whether that review is with the Pharmaceutical Advertising Advisory Board (PAAB), an internal Medical, Legal & Regulatory (MLR) team, or any other regulated workflow.

Advisory demo. All claim outputs are for illustration only. Medical Legal Review retains final authority.

Explore the Full Solution → Start a Sprint →
Specialty Brand Reality

Why Specialty Brands Drift Earlier

Oncology, hematology, and rare disease teams operate with tighter claim boundaries, denser evidence packages, narrower patient populations, and less tolerance for drift. That makes upstream discipline more valuable and upstream mistakes more expensive.

🎯

Narrow Claim Boundaries

Small wording changes can push beyond approved population, line of therapy, biomarker context, intended use, or supporting clinical nuance.

📚

Evidence Complexity

Claims often depend on precise endpoint language, subgroup context, comparator discipline, and stronger source linkage than general-market brands require.

⏱️

Higher Rewrite Cost

By the time issues surface in review, teams may already have invested in creative, internal rounds, medical input, and launch timing that are expensive to unwind.

🧭

More Reviewer Scrutiny

Medical, legal, and regulatory teams spend more time where claims are dense, evidence is nuanced, and wording discipline matters more.

See How It Works → Start a Sprint →
Who Feels the Problem First

Concerns Are Team Specific

Different teams feel the same breakdown in different ways.

Agency leaders

Reduce Rework and Protect Margins

Agencies feel the pain first through lost time, rework, and margin leakage. OmniVynt helps expose and reduce that hidden drag.

  • Preventable revision rounds and rewrite work
  • Version confusion across internal, client, and review teams
  • Need for a credible commercial case before annual SaaS commitment
See the Sprint →
Brand & commercial teams

Enhance Launch Readiness and Reduce Risk

Brand teams feel pressure when claims, evidence, and approvals drift. OmniVynt strengthens work upstream so assets enter review cleaner.

  • Launch delays caused by upstream drift
  • More channels, stakeholders, and asset versions to manage
  • Need for a cleaner handoff into MLR, PRC, or PAAB
Explore the Solution →
Medical, legal & regulatory

Improve Review Efficiency with Full Human Oversight

Review teams need to see what was flagged, why it matters, and which evidence supports it. OmniVynt improves consistency while keeping final authority intact.

  • No black-box recommendations
  • Need cited, reviewable rationale
  • Human authority remains non-negotiable
See Compliance Intelligence →
Oncology & specialty brand teams

Tighter Claims, Denser Evidence, Less Room for Drift

In oncology, hematology, and rare disease, the cost of upstream errors is higher. Narrower indications, more precise endpoint language, and denser evidence packages mean wording discipline matters earlier — not just at formal review.

  • Claim drift beyond approved population, line of therapy, or biomarker context
  • Evidence linkage gaps that only surface late in the review cycle
  • Higher rewrite cost when issues are caught at MLR or PAAB
Start a Sprint →
Live Demo

See OmniVynt Catch Risk on Your Claim in Seconds

Enter a claim or use a sample to see how OmniVynt works.

OmniVynt · Compliance Analysis Engine
Retrieving from PM and PAAB Code…
HIGH RISK
Compliant Rewrite Options
PM-Aligned
Guideline-Aligned
Patient-Outcome Focused
Advisory-only output. All flags are for illustration purposes. OmniVynt does not approve or certify any commercial material. Medical Legal Review retains full authority.
Where the Pressure Starts

The Real Cost Starts Before Review

Teams lose time before submission when claims come from multiple places, evidence is checked late, and versions multiply.

By then, the work is harder to defend, slower to fix, and more expensive to move into review.

1
The Rework Tax
Teams rebuild claims, recheck evidence, and fix issues late instead of working from controlled foundations.
2
Compliance Confidence
Teams need traceable findings, current sources, and clear rationale before formal review.
3
Trust & Evidence Discipline
Claims weaken when evidence is late, loosely matched, or hard to trace.
4
Omnichannel Complexity
More channels mean more versions, more stakeholders, and more chances for drift.
5
The Hidden Six Weeks
Most delay happens before submission: finding claims, checking evidence, aligning reviewers, and fixing late issues.
See How OmniVynt Fixes This → Book Demo →
Proven in PAAB workflows · Configurable across life sciences

OmniVynt Reduces Costs and Increases Efficiency Before Review

OmniVynt reduces risk and increases efficiency by catching common drafting issues before they create rework, delay, and review friction.

Three Issues OmniVynt Catches Early

1

Label Boundary Drift

Claims move beyond approved indications, intended use, or cleared parameters.

~25% of preventable resubmissions
2

Claim–Evidence Mismatch

Claims lack strong evidence or the right clinical framing.

~25% of preventable resubmissions
3

Citation & Reference Gaps

Missing or misaligned sources weaken defensibility in review.

~20% of preventable resubmissions
See How We Catch These → Test on Your Assets →
The OmniVynt Solution

A Clearer Workflow From Planning to Review

OmniVynt helps regulated life sciences teams plan content and activities, create in one shared workspace, identify compliance issues earlier, and move assets into formal review with clearer communication and sign-off.

Select each stage to see solution outputs
Stage 1 of 4, Brief

Plan content, collateral, activities, events, submissions, and more before creation begins

PlanVynt is the planning workspace for regulated marketing work. It helps teams organize content, collateral, activities, events, submissions, proposals, and other deliverables before creation begins, with clearer direction, shared communication, supporting material, and documented decisions in one place.

  • Plan content, collateral, activities, events, submissions, and more
  • Organize supporting material and source references
  • Align teams on scope, direction, and responsibilities
  • Keep early communication and decisions in one place
PlanVynt · Campaign Brief · Dupixent Asthma Q4
PM LOADED · TMA Mapped · PAAB Code 2024
HIGH RISK
"cures asthma", off-label claim
PAAB Code 2.10.2 · PM 4.1
REVIEW
"superior to Xolair", head-to-head data required
PAAB Code 5 · Comparative Claims
CLEAR
"reduces severe exacerbations in uncontrolled moderate-to-severe asthma"
Verbatim TMA · PM 4.1
Stage 2 of 4, Build

Create, review, and communicate in one shared workspace

Content Hub brings drafting, comments, revisions, version control, and review context into one place so teams stop losing time across email, calls, meetings, and disconnected files. It helps teams communicate more clearly, collaborate faster, and keep work moving without losing the thread.

  • Create and review in one shared workspace
  • Keep comments, revisions, and context in one thread
  • Reduce communication drag across teams and partners
  • Maintain version control across content and deliverables
Content Hub · 8 assets · Cross-referencing
Detail Aid v3
PM Aligned
Digital Banner v2
Claim drift detected
Email v1
Review: fair balance
Rep Aid v4
Ready for MLR
Campaign cross-check: "superior" appears in Banner but not supported in Rep Aid, inconsistency flagged · PAAB 5
Stage 3 of 4, Validate

Flag support, wording, and risk issues before formal review

Compliance Intelligence helps teams identify support gaps, risky wording, and potential compliance concerns earlier so fewer problems surface late in the process. It gives teams a cleaner path to review readiness by helping them strengthen work before it reaches formal review.

  • Surface support gaps and wording concerns earlier
  • Flag potential risk before formal review
  • Improve alignment between content and supporting material
  • Reduce preventable review pushback and rewrite cycles
OmniVynt · Compliance Review · Detail Aid v3
HIGH RISKOff-label implication
Trigger: "helps patients of all ages"
PM 4.1 authorizes adults only. "All ages" implies pediatric use. PAAB 2.10.2.
Rewrite: "indicated for adults 18+ with moderate-to-severe [indication]"
74%
Approval Probability Score
Resolve HIGH flag — est. 92% on resubmission
Stage 4 of 4, Handoff

Move cleaner assets forward with clearer sign-off

Review-Ready Handoff helps teams move assets into formal review with clearer approvals, attributed decisions, timestamps, and version history. That makes sign-off easier to trace, easier to defend, and easier to manage across multiple contributors.

  • Keep sign-off clear and attributable
  • Track decisions, timestamps, and version history
  • Improve handoff into formal review
  • Strengthen accountability across teams
Compliance Report · Detail Aid v3 · Export Ready
Generated: 2026-04-14 14:32 · Asset: Detail Aid Dupixent Asthma
Flags identified 2 HIGH · 3 REVIEW · 8 CLEAR
Rewrite options accepted 2 of 2 HIGH resolved
Post-rewrite approval score 92%
Export PDF Report
Export Word Dossier
What This Means for Your Team

Less Rework. Faster Launches. Protected Margins.

OmniVynt helps teams identify issues earlier, reduce rework, and move review-ready work forward faster.

⏱️

Half the Time, Same Team

Asset development drops from 22.75 to 10.75 hours. Same headcount, roughly double the throughput — without cutting corners on compliance.

53% faster · +112% throughput
✅

Fewer Rounds, Cleaner Submissions

Catch the flags that cause resubmissions before review begins. First-pass quality improves because risk is surfaced in week one, not at PAAB.

44% fewer resubmissions
📅

Compress the Launch Cycle

25–54 day internal cycles compress to 15–28 days. OmniVynt reduces the rounds your team controls, not PAAB’s process. Every internal stage gets faster.

~43% total cycle compression
🎯

Catch 70% of Preventable Issues

Label boundary drift, claim–evidence mismatch, and citation gaps account for the majority of preventable resubmissions. OmniVynt flags these before they reach formal review.

Based on PAAB 2025 Tag Report
Build Your Business Case → Start a Sprint →
ROI Calculator

Build Your Business Case in 30 Seconds

Model how much time, rework, and operating value OmniVynt could recover for your team.

Model the Business Case

30 seconds. Scenario model only.

Model the Business Case → Book Demo →

Prefer to walk through a modeled business case? Book Demo.

How to Engage

Four Ways to Work With OmniVynt

Start where it makes sense for your team. Every option is independent, no required sequence, no lock-in.

Not sure where to begin? A quick first signal: try the free demo scan. Ready to test on real assets: the 14-Day Proof Sprint is the most common first step. Specialty agency or validator: start with a pilot fit discussion.

Free · On This Page
Live Demo Scan
Single claim · Instant
See the logic before you engage
  • Enter any claim in the demo above
  • See risk level, source flag, and rationale
  • Glass-box output — no black box
  • No sign-up required
Try the Demo →
Paid · Contact Us
Per-Asset Scan
Single asset · Full analysis
A complete report on one real asset
  • Full asset compliance scan
  • Glass-box findings report
  • Source-cited flags + rewrite options
  • No platform commitment required
Contact Us →
Most Common
Paid · Refund If No Value
14-Day Proof Sprint
3–15 assets · 14 days
Proof of value on your real assets
  • Prioritized risk report across all assets
  • Evidence-based rewrite options
  • Documented business case + audit-ready docs
  • 60-minute debrief + action playbook
See the Sprint →
Paid · Custom Quote
Enterprise
Bespoke scope · Ongoing
Embed OmniVynt into your workflow
  • Full campaign and portfolio review
  • Configured to your PM, SOPs, and markets
  • Train-the-Trainer + compliance playbook
  • Security package + enterprise terms
Request Quote →

Each option stands on its own. If you start with the 14-Day Sprint and choose to continue, the sprint fee is credited in full toward Starter, Core, or Enterprise. If the sprint does not document clear value, the fee is waived. No lock-in at any stage.

Frequently Asked Questions

Frequently Asked Questions

No. OmniVynt is advisory-only. It helps teams identify issues earlier, strengthen claim and evidence alignment, and improve submission readiness before formal review begins. Medical, Legal, and Regulatory teams retain full authority.
OmniVynt is not just a scanner. It helps teams plan claims earlier, connect content to evidence, flag risk before submission, and move cleaner assets into formal review with more control and less rework.
OmniVynt is designed for regulated life sciences teams and agencies, including brand and commercial teams, medical, legal, and regulatory reviewers, and agency teams managing high-volume commercial workflows.
OmniVynt helps detect claim risk issues, evidence gaps, Product Monograph boundary issues, citation weaknesses, and other problems that often lead to revision cycles, rework, or weaker review readiness.
Yes. Agencies use OmniVynt to reduce avoidable revision cycles, protect margin, and improve the quality of assets before they reach clients or formal review. In-house teams use it to improve consistency, evidence discipline, and handoff quality.
No. OmniVynt is built around glass-box logic. Teams can see what was flagged, why it matters, and what source or rule supports the concern. That visibility is critical in regulated environments.
No. OmniVynt is built with strong relevance for Canadian regulated workflows and can be configured for broader regulatory environments, including U.S. requirements and internal review standards.
The value is not in removing human judgment. It is in improving visibility, consistency, and review readiness before formal review starts. OmniVynt helps reviewers inspect logic more clearly without giving up control.
Brand and commercial teams use OmniVynt to reduce upstream drift, improve alignment between claims and evidence, and move assets into review with greater consistency, speed, and control.
Agency teams use OmniVynt to expose hidden rework, reduce rewrite cycles, improve workflow clarity, and protect both client confidence and account profitability.
OmniVynt is designed for rapid activation. Teams can start with a sample scan, workflow review, or proof sprint to evaluate fit and demonstrate value without heavy IT lift.
No. OmniVynt supports earlier, better-informed decisions. Final interpretation, approval, and accountability remain with the appropriate human reviewers.
OmniVynt Solution Overview

Less Rework. Faster Review Readiness.

OmniVynt is an easy-to-adopt solution for regulated life sciences teams that need to reduce rework, improve accuracy, lower risk, and move assets into formal review with better control.

Easy to Start Less Rework Higher Throughput Lower Risk Shared Sign-Off
Why Teams Need This

Most delay happens before formal review

The problem is rarely one bad asset. It is a broken workflow before formal review: claims and supporting material drift apart, feedback fragments across tools, approvals are hard to trace, and teams spend too much time rewriting work that should have been right earlier.

🔁

Too Much Rework

Teams fix the same issue more than once because context, evidence, and reviewer comments are not in one place.

⚙️

Too Much Friction

Email, calls, comments, and file versions create communication drag and slow every handoff.

⚠️

Too Much Risk

Evidence gaps, unsupported wording, and unclear sign-off increase the chance of preventable review pushback.

📊

Not Enough Visibility

Leadership cannot improve throughput when bottlenecks, rewrite volume, and approval drag stay hidden.

The OmniVynt Solution

A Clearer Workflow From Planning to Review-Ready Handoff

OmniVynt helps regulated life sciences teams plan the work, create in one shared workspace, identify compliance issues earlier, and move assets into formal review with clearer communication and sign-off.

What buyers care about
  • ✓Easy to start
  • ✓Faster review readiness
  • ✓Shared accountability
  • ✓Clearer throughput visibility
How OmniVynt Works

Four connected stages that reduce rework before formal review

PlanVynt helps teams plan the work and align early decisions. Content Hub keeps drafting, comments, communication, and version control in one place. Compliance Intelligence flags issues earlier. Review-Ready Handoff makes approvals and sign-off easier to trace and defend.

🗂️

1. PlanVynt

Plan content, collateral, activities, events, submissions, and more before creation begins

PlanVynt is the planning workspace for regulated marketing work. It helps teams organize content, collateral, activities, events, submissions, proposals, and other deliverables before creation begins, with clearer direction, shared communication, supporting material, and documented decisions in one place.

💬

2. Content Hub

Create, review, and communicate in one shared workspace

Content Hub brings drafting, comments, revisions, version control, and review context into one place so teams stop losing time across email, calls, meetings, and disconnected files.

🚩

3. Compliance Intelligence

Flag support, wording, and risk issues before formal review

Compliance Intelligence helps teams identify support gaps, risky wording, and potential compliance concerns earlier so fewer problems surface late in the process.

✅

4. Review-Ready Handoff

Move cleaner assets forward with clearer sign-off

Review-Ready Handoff helps teams move assets into formal review with clearer approvals, attributed decisions, timestamps, and version history.

See it on your assets

Not sure if it fits your workflow? Show us one real asset.

Bring one anonymised asset and your target market. We’ll show OmniVynt catching risk on your actual claim types — no commitment required.

Book a Demo → See the 14-Day Sprint →
What Changes

What changes when upstream discipline improves

Teams that reduce upstream drift see the impact across every stage: fewer rewrites, cleaner handoffs, and faster movement into formal review.

✓

Less Rework

Fewer avoidable rewrites and fewer issues discovered late.

📈

Higher Throughput

Cleaner handoffs, less communication drag, and fewer stalled review cycles.

🛡️

Lower Risk

Better visibility into support, wording, and approval status.

⏱️

Faster Review Readiness

Teams start from stronger inputs and move cleaner assets into formal review faster.

See it on your own work

Bring a real asset. See the value in the first session.

Show a real asset. See where OmniVynt reduces friction, improves clarity, and shortens the path to review-ready work.

Book a Demo →
How It Works

Plan. Create. Validate. Execute.

See how OmniVynt moves teams from early planning to review-ready submission with less rework.

Plan · PlanVynt Create · Content Hub Validate · OmniVynt Execute · Campaign Manager
The Workflow

Four Connected Stages, One Clear Workflow

From brief through execution, OmniVynt reduces drift and keeps evidence traceable.

01
Plan
Define claims early, collaboratively
Import your PM at the brief, set guardrails early, and align the team before content starts.
02
Create
Structured, high-capacity development
Create in one workspace with reusable approved materials, collaboration, and version control.
03
Validate
Compliance intelligence with defensible audit trails
Flag risk early, suggest rewrites, and strengthen submission readiness with a clear audit trail.
04
Execute
Submit with confidence at scale
Coordinate execution across teams and export audit-ready reports with every asset.

Content Lifecycle

Scientific evidence
›
Claims framework
›
Content development
›
Compliance review
›
Medical Legal Review / PAAB submission
›
Market execution
✓
OmniVynt enables and strengthens every stage

Moving compliance upstream, and maintaining it throughout, is what drives the 53% development time reduction and 44% fewer resubmissions.

MLR Optimization

Reducing Medical Legal Regulatory Review Bottlenecks

Traditional review can run 5-6 cycles or more. OmniVynt intercepts risk earlier across the five critical MLR categories:

  • Editorial & Brand Guidelines
  • Market & Channel Compliance
  • Regulatory Compliance
  • Claim Substantiation
  • Fair Balance

Result: fewer cycles, cleaner submissions, and faster timelines.

Explore the Full Solution → Start a Sprint →

Optimize Your Life Sciences Content

OmniVynt connects evidence, claims, creative development, and MLR readiness in one workflow.

🔬

Scientific Evidence → Claims

Turn complex science into marketing-ready claims.

Generate compliant claims from publications and regulatory sources with linked evidence.

🗂️

Claims Library Creation & Maintenance

Turn approved materials into a living claims asset.

Deduplicate claims, organize variations, and keep every source traceable.

✍️

Creative & Content Development

Accelerate creation with compliant building blocks.

Access claims, disclosures, and citations faster with built-in pre-review validation.

⚖️

Medical, Legal & Regulatory Review

Cut review cycles and increase consistency.

Flag risks across all five MLR categories and standardize review quality across the portfolio.

The Result?
53%
faster content development
44%
fewer resubmissions
1-2
review cycles instead of 5-6

Based on validated OmniVynt benchmarks. Actual results vary by asset complexity, team structure, and internal review protocols.

Already seen enough?

Start with one asset. No IT setup required.

Send us 1–15 assets. We return a compliance risk report, rewrite options, and a documented business case in 14 days.

Start a Sprint → Book Demo →
Deployment & Integration

Start Lightweight. Expand When Value Is Proven.

OmniVynt integrates where you already work, not the other way around. Sprints require zero IT involvement. Platform deployments can shadow your existing approval workflows.

🔗

PromoMats Compatible

OmniVynt operates upstream of PromoMats, improving content quality before it enters the formal Medical Legal Review workflow.

⚡

Zero IT for Sprints

The 14-day sprint requires no technical integration. Send assets, receive reports. No platform access, no IT tickets, no changes to your workflow.

🔮

Shadow Mode & API

Shadow mode deployment available for parallel validation alongside existing review. API available for enterprise clients with existing workflow tools.

Get Started

See It Working on Your Assets

No platform commitment. No IT setup. Send us your assets and see OmniVynt in action within a week.

Start Proof Sprint → Book Demo
Tailorable · Canada-Ready · U.S.-Expandable

Review Claims, Codes and Compliance

Run assets through OmniVynt to identify risk, receive clearer rewrite options, and improve submission readiness.

Run a Compliance Check →
Advisory only, formal review authority remains with your team Canada pharma depth today, broader life sciences configuration supported PIPEDA compliant
Tailorability
Tailored to Your Regulatory Environment, Not a Generic Rule Engine.

OmniVynt adapts review logic based on your product type, claims framework, market, evidence standard, and internal requirements, not a one-size-fits-all ruleset.

📄

Label & Claims Scope

Configured to your Product Monograph, FDA labeling, approved indications, intended use language, contraindications, warnings, and current claim boundaries.

🏥

Product & Category Context

Aligned to the specific evidentiary, risk, and disclosure context for pharma, biotech, medical devices, medtech, diagnostics, AI/digital health, and adjacent regulated offerings.

🏢

Internal Standards & Governance

Incorporates your company or agency workflows, MLR standards, brand frameworks, evidence expectations, risk tolerances, and internal review processes.

🔄

Campaign-Level Consistency

Tracks claims and language across all assets in your campaign, flagging drift and inconsistency omnichannel.

📊

Evidence Standards

Applies your evidence quality standards, including unpublished data policies, citation requirements, and head-to-head data thresholds.

⚡

Actionable Outputs

Outputs are relevant, aligned, and immediately usable, not generic risk warnings requiring further interpretation.

What OmniVynt Identifies
Six compliance domains. Every asset.

OmniVynt evaluates the same categories that generate the highest proportion of preventable PAAB resubmissions.

PM Boundary Risks

Every claim checked against your Product Monograph, indication language, authorized use, contraindications, and dosing boundaries.

Evidence Gaps

Identifies claims lacking sufficient evidentiary support, misrepresenting study data, or citing unpublished data.

Fair Balance Issues

Evaluates whether safety/risk information is appropriately represented relative to efficacy claims per PAAB standards.

Citation Weaknesses

Flags missing, weak, or misrepresented citations, including unpublished data and conference abstracts without adequate qualification.

Superlative Language Risks

Detects phrasing implying superiority without adequate head-to-head data: "best," "leading," "most effective," "first-line."

Cross-Asset Inconsistencies

When multiple assets are submitted, cross-references claim language across all files, identifying drift, contradictions, and inconsistencies.

What Every Flag Is Grounded In
Three source layers. Every review anchored in them.

OmniVynt does not generate generic suggestions. Every output is grounded in the standards that apply to your environment.

Primary Regulatory Source

Market-Specific Codes & Regulations

PAAB and IMC in Canada today, with support for FDA/OPDP requirements, device and diagnostic marketing constraints, and other market-specific commercial or conduct standards as configured for your organisation.

View Example Source →
Primary Claim & Evidence Authority

Approved Labels, Intended Use & Evidence Sources

Health Canada Product Monographs, FDA-approved labeling, intended use statements, cleared indications, validation evidence, and other official claim authorities define what your teams can and cannot say.

View Example Authority →
Internal Governance Layer

SOPs, Review Standards & Brand Rules

Internal SOPs, MLR conventions, quality requirements, reviewer playbooks, partner constraints, and brand guardrails shape how your organisation actually operationalises compliant content development.

Configure for Your Environment →
Example Reviewer-Ready Source Blocks

Advertising & Commercial Codes

PAAB Code of Advertising Acceptance, FDA/OPDP requirements, IMC Code of Ethical Practices, and any other applicable commercial or ethical standards in your markets.

Primary Claim & Label Authorities

Health Canada Product Monographs, FDA-approved labeling and prescribing information, EMA SmPC (where relevant), and all other official claim authorities for your products.

Client-Specific Requirements

Internal SOPs, Medical Legal Regulatory review standards, brand guardrails, therapeutic-area policies, and any market-specific or company-specific rules you need enforced.

Every flag is anchored to the exact governing source and section — with clear rationale and reviewer-ready citations your team can verify in seconds.

Configure OmniVynt for Your Regulatory Environment →
Start Now

Request a Full Asset Analysis

Send us any asset. We return a complete compliance risk report, compliant rewrite options, and an audit-ready PDF in 14 days.

Request Full Asset Analysis → See Sprint Options Book Demo →
14-Day Proof Sprint

You Are Losing Time and Margin Before Review Even Starts

Most rework in regulated marketing is preventable. It builds upstream — in weak claims, late evidence checks, and versions that multiply before anyone flags the risk. The 14-Day Proof Sprint finds it on your real assets, documents the impact, and shows your team exactly what to fix.

Step 2 of 3 — or start here directly Service-led + AI-augmented No platform commitment required Fee waived if value is not documented
Start Your Sprint → Book Demo
3–15 assets. Fixed scope. Fee waived if value is not documented.
What Your Team Gets in 14 Days
Five deliverables. Ready to use the day we hand them over.

You send 3–15 assets plus briefs. We return everything your team needs to fix the issues, make the business case internally, and move into review stronger.

🔍 Prioritized Risk Report

Human + AI-augmented scan across claims, evidence, and compliance flags — mapped to your guardrails and the governing source for every finding.

✏️ Evidence-Based Rewrite Options

Every high-risk claim flagged with compliant alternatives and source-tied rationale your team can act on immediately.

📊 Documented Business Case

Modeled impact on rounds avoided, margin protected, and timeline compression — built to support internal sign-off.

📋 Audit-Ready Documentation

Exportable reports formatted for internal review, procurement review, or brand leadership — ready to share the day you receive them.

🎯 60-Minute Debrief + Playbook

Live walkthrough of every finding with your team, plus a prioritized action plan for the next asset cycle.

Timeline
1–2
Days 1–2
Kickoff + asset intake
3–10
Days 3–10
Analysis + rewrites
11–13
Days 11–13
Report build + QA
14
Day 14
Delivery + debrief
What Success Looks Like
“We protected margin on this campaign.”
“We avoided 2+ extra MLR rounds.”
“Assets entered review first-pass ready.”

Typical Outcomes

44%fewer resubmissions (1.6 → ~0.9 cycles)
53%faster asset development
12hrssaved per asset (22.75 → 10.75 modeled)

Based on PAAB 2025 Tag Report, 2026 fee schedule, and OmniVynt workflow benchmarks. Actual results vary by asset complexity and team structure.

Our Guarantee
If we don’t document clear value, the sprint fee is waived.

“The hidden friction was always claim drift and evidence gaps showing up at PAAB submission. OmniVynt catches that upstream, exactly where we needed it.”

MD, Managing Director, Independent Health Agency

We document operational or commercial value based on avoided rework, fewer revision cycles, protected margin, or timeline impact. If that value isn’t documented to your satisfaction, you don’t pay.

How We Document Value

  • Hours saved × blended team cost
  • PAAB or MLR resubmission fees avoided
  • Documented timeline impact for brand and commercial teams
  • Compliance risk mitigation that is qualitative but material

Payment Terms

  • New clients: 100% on delivery, net-30
  • Established clients: net-30 available
  • No hidden fees
  • No platform upsell required
Common Questions
Before you book.
Does this change our Medical Legal Review or PAAB process?+
No. The sprint runs alongside your existing workflow. You send assets; we return risk reports and rewrite options. PAAB, MLR, and PRC retain full approval authority — that is non-negotiable and written into every engagement.
What format do assets need to be in?+
Any format your team already uses: PDF, DOCX, PPT, or pasted copy. No special preparation required. We configure analysis to your Product Monograph and applicable ruleset before Day 1.
How quickly can we start?+
Typically within one week of agreement. Day 1 begins with a kickoff call to confirm scope, asset list, and PM loading. The 14-day clock starts from asset submission.
Is there a platform commitment after the sprint?+
No. The sprint is a standalone engagement. If value is demonstrated, we can discuss next steps — but that conversation happens only after you’ve seen results.
What happens to our data?+
All client data is strictly isolated. No cross-client model training — ever. Assets are deleted after analysis is complete. Every engagement includes an NDA. The platform is PIPEDA compliant and no PHI is processed.
How is this different from generic AI tools?+
OmniVynt is glass-box, not black-box. Every flag shows: (1) the exact trigger text, (2) the source authority — a specific PAAB clause, PM section, or IMC principle — and (3) plain-language rationale. Your Medical Director can verify any flag against the source document in 30 seconds.
Is this only for PAAB-bound pharma?+
No. While deepest today in Canadian pharma (PAAB, IMC, Health Canada), the sprint is configurable for FDA/OPDP workflows and across pharma, biotech, medical devices, medtech, diagnostics, and AI/digital health. Tell us your market and product type — we adapt the review logic.
Is This the Right Move Right Now?
The sprint works best in specific conditions.
✓

Good fit right now

  • Teams with 3–15 live or near-live assets moving toward review
  • Agencies that need documented value before a broader platform commitment
  • Commercial teams willing to share anonymized assets, briefs, and review context
  • Groups that want fast proof of value before changing workflow more broadly
✗

Not the right fit yet

  • Teams with no active asset flow or live review pressure
  • Buyers expecting autonomous approval rather than advisory support
  • Organisations looking for full enterprise rollout before a pilot proves value
  • Groups unable to share sample materials or key stakeholder context
After the Sprint
Four outcomes. You decide.

At the end of 14 days you have the findings, the business case, and the documentation. What happens next is entirely your call — including doing nothing.

👋

Take the findings and walk away

Everything we delivered is yours to keep — the risk report, rewrite options, and business case. No follow-up required. If the sprint did not document clear value, the fee is waived entirely.

No obligation. No upsell. The work speaks for itself.

📈

Continue with Starter

Expand to a focused 3-asset engagement. Same team, same configuration — pick up where the sprint left off with no restart.

Sprint fee credited in full · 3 assets · Contact us for pricing

Ask About Starter →
🌟
Most Popular

Continue with Core

Full campaign analysis across 5–8 assets. Sprint fee credited in full. Adds a Train-the-Trainer session, compliance playbook, and one fully rewritten asset.

Sprint fee credited in full · 5–8 assets · Contact us for pricing

Ask About Core →
🏛️

Continue with Enterprise

Move directly into a bespoke ongoing engagement — configured to your portfolio, markets, SOPs, and internal standards. Sprint fee credited in full toward your custom quote.

Sprint fee credited in full · Custom scope · Custom quote

Request Enterprise Quote →
🔒

There is no pressure to continue and no automatic renewal. If you choose to move forward to any paid option, the sprint fee is credited in full. If the sprint does not document clear value, the fee is waived. Either way you keep the work and owe nothing more.

Ready to See What’s Actually at Risk?

Tell us your asset types, markets, and current review timeline. We’ll scope the right sprint and get started within a week.

Advisory-only outputs. OmniVynt does not approve, certify, or guarantee acceptance of any commercial material. Medical Legal Review retains full authority. PIPEDA compliant. No PHI processed.
Start Your 14-Day Sprint →
3–15 assets. Fee waived if value is not documented. No platform commitment.
Intelligence

Marketing Intelligence and Security for Regulated Teams

Tailored regulatory references, practical review guidance, and secure configuration built around your products, markets, and internal standards.

Configured Inputs

We don't offer a generic library. We tailor to your needs

  • 📘Reference authority: Your Product Monograph, FDA label, or intended use statement
  • 🧭Internal standards: Your company SOPs, MLR conventions, and brand guardrails
  • 🌐Market-specific codes: PAAB (CA), FDA/OPDP (US), EMA (EU), PMDA (JP), NMPA (CN), and more
  • ⚖️Industry ethics codes: IMC, PhRMA, EFPIA, JPMA, and related standards
  • 🧪Clinical and commercial context: Therapeutic-area policies, evidence standards, and risk tolerances

Tell us your scope. We configure the review logic around it.

Configure Your Review Environment →
Start With What Matters to You

Start by market, product type, or workflow need.

By Market
  • 🇨🇦 Canada: PAAB, IMC, Health Canada DPD
  • 🇺🇸 United States: FDA/OPDP, PhRMA Code, FTC Guidelines
  • 🇪🇺 Europe: EMA, EFPIA, National Competent Authorities
  • 🌏 Asia-Pacific: PMDA (JP), NMPA (CN), HSA (SG), TGA (AU)
  • 🌍 Global: ICH, WHO, cross-border commercial standards
By Product Type
  • Pharmaceuticals (Rx, OTC)
  • Medical Devices (Class I-III)
  • Diagnostics & IVDs
  • AI / Software as a Medical Device (SaMD)
  • Digital Health & Wellness
By Workflow Need
  • Claims substantiation & evidence mapping
  • Fair balance & risk communication
  • Comparative claims & head-to-head data
  • Social media & digital channel compliance
  • Launch readiness & first-submission quality
External Regulatory Sources

Authoritative references we configure into your review logic.

Canada

PAAB Code of Advertising Acceptance, Health Canada Drug Product Database, and the Innovative Medicines Canada Code.

United States

FDA advertising rules, current OPDP letters, and the PhRMA Code.

Europe & Global

EMA product information guidance, the EFPIA Code of Practice, and ICH guidelines.

Need a source not listed? Tell us. We will integrate it.

OmniVynt Guides & Analysis

Practical frameworks built for regulated life sciences teams.

Compliance Strategy

Claims Library Guide: Building a Label-Aligned Foundation

Structure claims so they map directly to your Product Monograph or FDA label, reducing evidence gaps and strengthening first-pass review quality.

OmniVynt Guide · 8 min read
Compliance Strategy

Fair Balance in Digital Channels: A Practical Framework

Adapt risk communication for social, email, and interactive media while maintaining fair balance, clarity, and regulatory alignment.

OmniVynt Guide · 10 min read
Agency & Commercial Ops

The True Cost of Preventable Resubmissions

See how avoidable rework, fee exposure, and margin erosion build across PAAB, FDA, and broader MLR workflows.

OmniVynt Analysis · 6 min read
Agency & Commercial Ops

MLR Handoff Checklist: What to Send, What to Flag

Reduce review friction by sending pre-vetted, source-anchored assets to Medical, Legal, and Regulatory review.

Free Download · PDF
Launch & Expansion

First-Submission Readiness: A Global Launch Primer

Prepare commercial content for simultaneous or staggered market entry without multiplying avoidable review cycles.

OmniVynt Guide · 12 min read
Free Download

Download Free MLR Checklist

Use a practical handoff checklist to improve source anchoring, reduce rework, and prepare stronger assets for formal review.

Official Standards Paired to Each Guide

These are the most useful regulatory and workflow references to pair with each OmniVynt guide so the page leads somewhere practical, not to thin placeholder content.

Claims Alignment

Claims Library Guide: Best-Fit Support

Use official PAAB and FDA labeling and promotion standards to keep claims mapped to approved wording, supported by evidence, and easier to defend in review.

Fair Balance

Digital Fair Balance: Best-Fit Support

Use PAAB fair-balance guidance and FDA promotion standards to judge prominence, access to risk content, and whether channel design is distorting benefit-risk balance.

Resubmissions & Workflow

Resubmissions Analysis: Best-Fit Support

Pair commercial waste analysis with live enforcement signals and practical MLR workflow references that show where delays, rework, and traceability failures usually begin.

Review Handoff

MLR Handoff Checklist: Best-Fit Support

Use this with practical handoff discipline: clear source packets, version control, flagged sensitivities, and evidence traceability before content enters formal review.

Launch Readiness

Submission Readiness Primer: Best-Fit Support

Use official PAAB, FDA, and EMA reference points to align core claims, risk language, market differences, and submission expectations before launch content starts to branch.

The point is not to dump regulations onto users. It is to connect each OmniVynt guide to the exact standards and process references that help teams improve claims alignment, fair balance, evidence support, and review readiness.

Your Rules, Your Review

OmniVynt is not a static rule engine. It is a configurable review environment built around your requirements.

  • Company Policies: Upload your SOPs, brand guidelines, MLR playbooks, or risk thresholds
  • Market Rules: Select primary and secondary markets; we layer applicable codes and regulations
  • Product Context: Define product class, indication boundaries, evidence standards, and claim types
  • Workflow Integration: Align outputs to your existing review tools, approval stages, and documentation needs

We work with you to configure it right.

Schedule a Configuration Session →
Security & Trust

Built for Regulated Environments

OmniVynt is designed for the data handling, privacy, and governance requirements of life sciences teams operating in regulated markets.

🔒

Data Isolation

Every client's data is strictly isolated. No cross-client model training, ever. Your assets are never used to train shared or public AI models.

🇨🇦

PIPEDA Compliant

OmniVynt is built to PIPEDA requirements. For US clients, HIPAA compliance is in scope. Canadian hosting available.

📋

No PHI Processed

OmniVynt handles commercial materials only. No patient-level PHI is ingested or processed at any stage.

🗑️

Data Deletion

All submitted assets are deleted after analysis is complete. No retention of client materials beyond the agreed scope.

📄

NDA on Every Engagement

Every sprint and platform engagement includes a mutual NDA. All discussions and materials are treated as confidential.

✅

SOC 2 Ready

SOC 2 Type II documentation available on request. Certifications confirmed per deployment with audit reports and scope statements.

Request the Security Package

Full data handling policy, HIPAA/GDPR controls, AI governance manifesto, and compliance alignment documentation, available for procurement review.

Request Security Package →
Compliance Strategy

Claims Library Guide Building a Label-Aligned Foundation

Build a usable claims foundation that maps directly to approved label language, evidence, and market rules so downstream drafting is faster and easier to defend.

OmniVynt Guide
8 min read
Claims alignment focus

A good claims library is not a folder of old copy. It is a controlled system that shows which claims are usable, what evidence supports them, where the approved wording comes from, and where each claim can or cannot travel by market, audience, and channel.

What to structure
  • Claim text linked to exact label or approved source language
  • Supporting evidence with excerpts, references, and usage notes
  • Audience and channel limits for each claim
  • Version history so teams know what changed and why
  • Comparison flags for superiority, consistency, and fair balance risk
What good looks like
  • Writers can pull approved claims without guessing
  • Reviewers can trace each claim back to its source quickly
  • Teams know which claims are reusable versus net new
  • Evidence gaps are found before creative work expands
  • Localization starts from a controlled core rather than scattered files
Official support for this topic

Use these sources when building or validating a label-aligned claims foundation.

PAAB Code of Advertising Acceptance →FDA Promotional Materials Guidance →OPDP FAQs →
Back to Resources →
Compliance Strategy

Fair Balance in Digital Channels

Use a practical framework for judging prominence, access, and readability of risk information across websites, email, social, and interactive media.

OmniVynt Guide
10 min read
Digital channel focused

Fair balance breaks down most often when teams compress benefit claims into the visible surface and push risk language into low-visibility placements. The question is not only whether risk exists somewhere. It is whether the user receives a balanced impression of benefit and risk in the way the channel is actually experienced.

Questions to ask
  • Is benefit language more prominent than risk language?
  • Does the design force extra clicks to reach material risk content?
  • Does the format truncate or soften important limitations?
  • Would a regulator say the overall impression is balanced?
  • Are links and disclosures obvious enough for real users?
Channel adjustments
  • Social: tighten claims and link clearly to risk information
  • Email: keep risk cues visible before the call to action
  • Web: avoid burying material safety below long scroll paths
  • Interactive tools: make risk access persistent, not optional
  • Video: match spoken or visual benefits with clear risk treatment
Official support for this topic

Use these sources to judge digital fair balance and risk-presentation choices.

PAAB Fair Balance Guidance →PAAB Fair Balance Weblink Examples →FDA OPDP Office →
Back to Resources →
Agency & Commercial Ops

The True Cost of Preventable Resubmissions

Break down how rework, review fees, delay, and lost reviewer attention build when submission quality is weak before formal review starts.

OmniVynt Analysis
6 min read
Commercial ops lens

Most teams can feel review drag. Fewer can show where it starts. The point of this analysis is to expose the avoidable cost building before formal review: time spent rebuilding claims, chasing evidence, reconciling versions, paying for extra cycles, and waiting for already-busy reviewers to recheck preventable issues.

What the cost includes
  • Unbillable rewrite hours and PM coordination time
  • External review fees and avoidable cycle extensions
  • Delayed channel launch or market activation
  • Reviewer attention pulled toward low-value issues
  • Margin erosion when revision rounds stack
What to measure
  • Revision frequency by asset and campaign
  • Time in queue versus time in active review
  • Source defects and missing evidence at submission
  • Reuse rate of approved claims and modules
  • Wait time between rounds and owner handoffs
Useful external references

Use enforcement and workflow sources together. Regulators show what goes wrong; workflow references show where the operating waste begins.

FDA Pharma Warning Letters →MLR Review Process Overview →MLR Efficiency Strategies →
Back to Resources →
Agency & Commercial Ops

MLR Handoff Checklist What to Send, What to Flag

Prepare a cleaner handoff into Medical, Legal, and Regulatory review with source-anchored materials, version context, and clear risk flags.

Free Download
Checklist format
Review readiness

A strong handoff does not just send the asset. It sends the logic around the asset: what changed, which sources matter, where the sensitivities are, and which items need explicit reviewer attention. That reduces avoidable back-and-forth and makes reviewer time more productive.

Send with the asset
  • Current claim list with source mapping
  • Key references and supporting excerpts
  • Version history and major changes since last round
  • Market constraints, audience limits, and channel context
  • Known dependencies on label, policy, or interpretation
Flag before review
  • Comparative or superiority language
  • Safety wording and fair balance sensitivities
  • Any claim not lifted directly from approved wording
  • Localization changes that could alter meaning
  • Sections where commercial pressure may overreach the source base
Workflow references

Use these as practical support for handoff discipline, role clarity, and review efficiency.

Cross-Functional Handoff Strategies →Review Process Bottlenecks →
Back to Resources →
Launch & Expansion

First-Submission Readiness A Global Launch Primer

Align the core claim set, evidence package, market differences, and owner roles early so launch content does not fragment into duplicate review effort.

OmniVynt Guide
12 min read
Launch focused

Global launch content slows when each market starts adapting assets from a weak core. Submission readiness means establishing what stays constant, what changes by market, what evidence is acceptable, and who owns the approval path before localization starts to multiply work.

What to align early
  • Core label language and market-specific variations
  • Evidence hierarchy and acceptable source set
  • Localization rules, timing, and accountable owners
  • Fair balance expectations by market and channel
  • Submission dependencies that can block launch timing
Where launches stall
  • Markets adapt assets without a controlled core
  • Evidence expectations differ but are not mapped early
  • Risk language changes are left too late
  • Owner roles blur across brand, regulatory, and agencies
  • Teams discover regional constraints after creative work expands
Official support for this topic

Use these sources to anchor market-readiness planning before launch materials begin to branch.

PAAB Code →FDA Promotional Submission Guidance →EMA Product Information Requirements →
Back to Resources →
Business Case Calculator

Build the Business Case

Illustrative model for regulated review workflows.

Advisory-only AI
Conservative benchmarks
Built for regulated review workflows
Scenario Model

Model OmniVynt ROI

Based on PAAB 2025 Tag Report and regulated workflow benchmarks. Defaults reflect PAAB averages — adjust to match your team.

Your Operating Profile

Defaults are PAAB 2025 averages. Drag to match your team.

150
1400
3.2
1.06.0
1.6
0.54.0

Fixed assumptions (PAAB 2025 benchmarks): $159/hr blended labour · 10 hrs/rework round · $167/PAAB resubmission · remediation at $6,000/asset. Remediation rate: 35% of regulated promotional assets require costly hard fixes before approval — redesign, copy overhaul, or re-filing. OmniVynt's upstream compliance screening reduces that to 20%, saving $900 per asset on average. Combined with 34% fewer rework rounds and 44% fewer PAAB resubmissions, OmniVynt delivers an average ~39% reduction in total per-asset cost at PAAB averages. All figures are illustrative expected values — not a guarantee. Actual results vary.

Estimated annual savings
$409,518
Expected value across your asset volume · not a guarantee
$2,730 Avg. saving per asset
$259,740 Labour recovered — 34% fewer rework rounds
$14,778 PAAB fees avoided — 44% fewer resubmissions
$135,000 Remediation saved — 35% of assets need costly fixes at baseline; OmniVynt cuts that to 20%
Book Demo →

We'll walk through your results and show exactly where OmniVynt recovers time, cost, and compliance risk.

Why This Matters

You're Not Just Saving Time, You're Building a Defensible Business Case

Model recovered capacity, lower rework, and faster movement toward review.

Every preventable resubmission costs more than a fee. It also consumes hours and delays downstream activity.

What Your Results Mean

How to Read the Numbers

Metric What it means
Estimated annual savings Total gross savings across your asset volume — labour, PAAB fees, and remediation combined
Avg. saving per asset How much OmniVynt recovers per asset — meaningful from asset one
Labour recovered Value of rework rounds eliminated — 34% fewer internal review cycles at $159/hr × 10hrs
PAAB fees avoided 44% fewer resubmissions × $167/iteration — direct hard-cost reduction
Remediation savings Remediation rate drops 35% → 20% — fewer assets needing costly hard fixes at $6,000/asset

Ready to See Your Actual Numbers?

The calculator uses conservative benchmarks. Your 14-Day Proof Sprint documents the working business case on your actual assets.

  • Compliance risk report on 3-15 real assets
  • Documented business-case dashboard (your numbers)
  • PAAB / PM / IMC source citations on every flag
  • No platform commitment required
Book Demo → Start 14-Day Proof Sprint →

Use the sprint to replace assumptions with your own asset flow, review history, and stakeholder context.

Built for life sciences teams navigating PAAB, FDA/OPDP, EMA, and internal MLR compliance, without the operational drag.

Contact
Start Reducing Rework and Review Friction Today.

Tell us your scope, products, and markets. We'll tailor the demo to your claims, evidence boundaries, and channels, or route you straight to a sprint, security, pilot-partner, or KOL conversation.

📅

Book Demo

Bring 1–2 anonymised assets and your target markets. We'll show OmniVynt working on your actual claim types.

Book Demo →
🚀

Start a 14-Day Sprint

Compliance gaps identified on 3-15 real assets. Business case documented in 14 days.

View Sprint Options →
🔒

Security Package

Data handling policy, HIPAA/GDPR controls, AI governance manifesto, and compliance alignment documentation.

Request Security Package →
🤝

Pilot Partners, Specialty Agencies & Validators

Explore founding pilot participation, workflow feedback, validator conversations, or specialty agency partnerships focused on oncology, hematology, rare disease, and other evidence-dense PAAB-reviewed brands.

Discuss Pilot Fit →

Send Us a Message

We respond within one business day. All information is treated as confidential.

We respond within one business day. All information is treated as confidential. PIPEDA compliant.

What to Expect

  • Response within one business day
  • We'll ask about your assets, markets, and current review cycle
  • Tailored demo using your claim types where possible
  • No commitment required for the first conversation
  • All discussions subject to mutual NDA if preferred

"The hidden friction was always claim drift and evidence gaps showing up at PAAB submission. OmniVynt catches that upstream, exactly where we needed it."

MD, Managing Director, Independent Health Agency
FAQ

Frequently Asked Questions

Common questions from commercial, compliance, agency, medical, regulatory, and quality stakeholders across regulated life sciences.

Does OmniVynt replace PAAB, Medical Legal Review, or internal regulatory review?+
No. OmniVynt is advisory-only. It improves what goes into formal review, it does not approve, certify, or guarantee acceptance of any material. PAAB, Medical Legal Review, and PRC retain full authority over all commercial approvals. This is non-negotiable in our contract and on every deliverable.
Is this black-box AI? How do we verify the flags?+
OmniVynt uses glass-box AI with RAG (Retrieval-Augmented Generation). Every flag shows: (1) the trigger text, the exact snippet flagged; (2) the source authority, specific PAAB code clause, PM section, or IMC Code principle; (3) the rationale, plain-language explanation. Your Medical Director can verify any flag in 30 seconds. We don't ask for trust, we show the work.
What rules does OmniVynt support?+
In Canada: PAAB Code of Advertising Acceptance and Health Canada guidance. In the US: FDA prescription drug advertising requirements including fair balance and restrictions on misleading claims. Additional rulesets added per client configuration.
What happens to our data? Is this PIPEDA compliant?+
All client data is strictly isolated, no cross-client model training, ever. Vynt Intelligence retains platform IP; you retain full ownership of your assets. Every engagement includes an NDA. The platform is PIPEDA compliant. No PHI is processed, we handle commercial materials only.
Is PAAB preclearance still required?+
Yes. OmniVynt is upstream preparation, it improves the quality of what goes into required reviews, not a substitute for them.
What's the difference between OmniVynt and PromoMats?+
PromoMats manages commercial material workflow and formal review. OmniVynt is upstream intelligence that improves the quality of what enters any workflow system. OmniVynt is designed to complement, not replace, existing approval platforms.
Are you SOC 2 or ISO 27001 certified?+
Certifications are confirmed per deployment and disclosed in the Security Package. We only claim certifications when audit reports and scope statements exist, confirm current status with our team.
How quickly can a sprint start?+
Typically within one week of signed agreement. Day 1 begins with a kickoff call to confirm scope, asset list, and PM loading. The 14-day clock starts from asset submission.

Still have questions? Talk to the OmniVynt team.

Contact Us → See the Sprint → Explore the Solution →
Launch Readiness

Compliance Readiness Before Launch Day

Launches compress every timeline. OmniVynt helps teams build stronger content infrastructure before the first asset reaches formal review.

Launch teams face unique compliance pressure.

A new launch means new claims, new evidence boundaries, and a team learning the review environment in real time. OmniVynt builds that foundation upstream, so your first submission is stronger whether you are launching a drug, device, diagnostic, or AI/Digital Health solution.

Launch Readiness Sprint →
About Us

For Regulated Life Sciences Teams

We are a commercial workflow intelligence platform.

Not a generic compliance checker. A platform that improves how content is planned, created, validated, and executed across regulated life sciences workflows.

What We Are

  • A commercial workflow intelligence platform for regulated life sciences teams
  • Deep today in PAAB, IMC, and Health Canada workflows
  • Relevant across pharma, biotech, medical devices, medtech, diagnostics, and AI/digital health
  • Configurable for FDA/OPDP, label-based, and client-specific requirements
  • Advisory-only, Medical Legal Review retains full authority
  • Glass-box AI, every flag is verifiable
  • Sprint-first, prove value before commitment

What We Are Not

  • ✗A compliance checker that replaces Medical Legal Review
  • ✗An AI tool that approves content
  • ✗A generic rule engine with no context
  • ✗A replacement for regulatory expertise
  • ✗A workflow tool requiring heavy IT implementation
Start Your Proof Sprint →
Legal

Privacy Policy

How Vynt Intelligence Inc. collects, uses, and protects your information.

Effective date: January 1, 2025  |  Last updated: April 12, 2026

1. Who We Are

Vynt Intelligence Inc. ("OmniVynt," "we," "us," or "our") provides commercial workflow intelligence software for regulated life sciences teams. Our principal place of business is in Canada.

2. Information We Collect

Information you provide: When you fill out a form, book a demo, or contact us, we collect your work email address, company name, job role, and any message content you submit.

Usage data: We may collect anonymised, aggregated data about how visitors interact with this website (e.g. pages visited, time on site) using privacy-respecting analytics. We do not use third-party advertising trackers.

Platform data: During a Proof Sprint or platform engagement, you may upload commercial materials (e.g. claims, draft assets). These are processed solely to deliver the agreed service and are deleted after analysis is complete unless otherwise agreed in writing.

3. How We Use Your Information

We use the information we collect to: respond to your enquiry or demo request; deliver and improve the OmniVynt platform and services; communicate about your engagement, account, or sprint; and comply with legal obligations.

We do not sell, rent, or share your personal information with third parties for their marketing purposes.

4. Data Protection & Retention

We implement commercially reasonable administrative, technical, and organisational measures to protect your data. Client data is strictly isolated; no cross-client model training occurs.

Contact information is retained for as long as necessary to maintain the business relationship or as required by law. Uploaded commercial materials are deleted after analysis is complete unless a longer retention period is agreed in your engagement terms.

5. PIPEDA Compliance

We comply with Canada's Personal Information Protection and Electronic Documents Act (PIPEDA). You have the right to access, correct, or request deletion of your personal information. To exercise these rights, contact us at the address below.

6. International Transfers

If you are located outside Canada, your information may be transferred to and processed in Canada. By submitting your information, you consent to this transfer. For clients requiring Canadian-only hosting, this is available upon request.

7. Cookies & Tracking

This website uses only essential cookies required for site functionality (e.g. session state, page routing). We do not use advertising cookies, retargeting pixels, or cross-site tracking technologies.

8. Children's Privacy

OmniVynt is a business-to-business platform. We do not knowingly collect personal information from individuals under the age of 18.

9. Changes to This Policy

We may update this Privacy Policy from time to time. Material changes will be noted by updating the "Last updated" date above. Continued use of the site after changes constitutes acceptance of the revised policy.

10. Contact

For privacy-related enquiries, data access requests, or complaints, please contact us through our Contact page.

Legal

Terms of Use

The terms governing your use of the OmniVynt website and platform.

Effective date: January 1, 2025  |  Last updated: April 12, 2026

1. Acceptance of Terms

By accessing or using the OmniVynt website or platform (the "Service"), you agree to be bound by these Terms of Use. If you do not agree, do not use the Service. If you are using the Service on behalf of an organisation, you represent that you have the authority to bind that organisation to these terms.

2. Description of Service

OmniVynt provides advisory commercial workflow intelligence tools for regulated life sciences teams. All platform outputs are advisory only. OmniVynt does not approve, certify, or guarantee acceptance of any commercial material by any regulatory body, review committee, or third party. Final interpretation, approval, and accountability for all compliance and regulatory decisions remain with the appropriate human reviewers within your organisation.

3. No Professional Advice

Nothing on this website or within the OmniVynt platform constitutes legal, regulatory, medical, or professional advice. The information and outputs provided are for informational and workflow support purposes only. You should consult qualified professionals for decisions regarding regulatory compliance, legal matters, or medical claims.

4. Illustrative Metrics & Projections

All metrics, statistics, time savings, cost projections, approval probability scores, and ROI estimates presented on this website or within the platform are illustrative estimates based on modelled workflows, published industry data (e.g. PAAB 2025 Tag Report, 2026 fee schedule), and internal benchmarks. They do not constitute guarantees or promises of specific outcomes. Actual results vary by asset complexity, team structure, review process, and other factors.

5. Intellectual Property

All content, design, code, trademarks, and intellectual property on this website are owned by or licensed to Vynt Intelligence Inc. You may not reproduce, distribute, or create derivative works from any part of this website without prior written consent.

Materials you upload to the platform remain your property. By uploading, you grant OmniVynt a limited, non-exclusive licence to process those materials solely for the purpose of delivering the agreed service.

6. Limitation of Liability

To the maximum extent permitted by applicable law, Vynt Intelligence Inc. and its officers, directors, employees, and agents shall not be liable for any indirect, incidental, special, consequential, or punitive damages, including but not limited to loss of revenue, loss of data, regulatory penalties, or reputational harm, arising from or related to your use of the Service. Our total aggregate liability for any claim arising from or related to the Service shall not exceed the fees paid by you to Vynt Intelligence Inc. in the twelve (12) months preceding the claim.

7. Disclaimer of Warranties

The Service is provided "as is" and "as available" without warranties of any kind, whether express or implied, including but not limited to implied warranties of merchantability, fitness for a particular purpose, and non-infringement. We do not warrant that the Service will be uninterrupted, error-free, or that any outputs will achieve any specific regulatory outcome.

8. User Responsibilities

You are responsible for: maintaining the confidentiality of any account credentials; ensuring that materials you upload do not violate the rights of any third party; and making your own independent compliance and regulatory decisions. You agree not to misuse the Service, including attempting to reverse-engineer, scrape, or access the platform in any unauthorised manner.

9. Governing Law

These Terms shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein, without regard to conflict of law principles. Any dispute arising from these Terms or your use of the Service shall be subject to the exclusive jurisdiction of the courts located in Ontario, Canada.

10. Changes to These Terms

We may update these Terms of Use from time to time. Material changes will be noted by updating the "Last updated" date above. Continued use of the Service after changes constitutes acceptance of the revised terms.

11. Contact

For questions about these Terms, please contact us through our Contact page.

← Events & Insights Contact Us
Events & Insights

Webinars

Practical sessions for regulated marketing teams on reducing rework, strengthening claims, and moving cleaner assets into review. Reserve your spot before dates are confirmed.

Webinar Coming Soon

Why Your Assets Aren’t Review-Ready Before They Reach PAAB or MLR

📅 Date TBD 💻 Live Virtual

Most avoidable delay in regulated marketing does not begin in formal review. It starts earlier — in weak briefs, claim drift, late evidence checks, and assets that look draft-complete but are not truly review-ready. By the time issues surface at PAAB or MLR, the cost to fix them is already high.

This session is for brand teams, agencies, and MLR professionals who want to understand where pre-review breakdown begins and what practical steps can move cleaner work into formal review faster. You will leave with a clearer picture of where your upstream process leaks, what review-readiness actually requires, and which workflow changes have the most immediate impact on resubmission rates and cycle time.

Date and speakers will be confirmed soon.

Webinar Coming Soon

When Claims Move Faster Than Evidence: The Upstream Gap That Causes Most Resubmissions

📅 Date TBD 💻 Live Virtual

Claims drift when evidence is checked too late. The result is avoidable rewrites, weaker reviewer confidence, and assets that reach PAAB or MLR carrying risk that should have been caught upstream. For most teams, this is not a knowledge problem — it is a workflow and timing problem.

This session is for brand teams, agencies, and medical-regulatory professionals dealing with late-stage evidence challenges and resubmission cycles. You will leave with a clearer understanding of where claim-evidence gaps form, how to catch them earlier in your workflow, and what stronger review-readiness looks like before an asset reaches formal review.

Date and speakers will be confirmed soon.

Pilot Partners & KOLs

Founding Pilot Program for Agencies, Early Team Partners, and KOLs

OmniVynt is opening a controlled group of founding relationships. Early participants get preferred terms, closer workflow input, and a chance to help shape the category.

The best early fit is teams with real asset flow, real review friction, and a reason to prove value quickly.

Pharma and Health Agencies

Best fit when revision drag, cross-client complexity, and margin leakage are already visible.

Specialty Brand & Evidence-Dense Teams

Oncology, hematology, rare disease, and other PAAB-reviewed brands where claim boundaries are narrow and upstream drift is costly.

Pilot Partners and KOL Conversations

For operators and experts who want earlier access and a role in shaping the workflow.

Discuss Pilot or Validator Fit →

Broad platform, focused launch: start where review friction and asset flow already matter.

Explore the Solution First → See the Sprint →